|Home | About | Journals | Submit | Contact Us | Français|
GABAA receptors (GABAARs) are the main inhibitory neurotransmitter receptors and have long been implicated in mediating at least part of the acute actions of ethanol. For example, ethanol and GABAergic drugs including barbiturates and benzodiazepines share many pharmacological properties. Besides the prototypical synaptic GABAAR subtypes, nonsynaptic GABAARs have recently emerged as important regulators of neuronal excitability. While high doses (≥100 mM) of ethanol have been reported to enhance activity of most GABAAR subtypes, most abundant synaptic GABAARs are essentially insensitive to ethanol concentrations that occur during social ethanol consumption (<30 mM). However, extrasynaptic δ and β3 subunit-containing GABAARs, associated in the brain with α4or α6 subunits, are sensitive to low millimolar ethanol concentrations, as produced by drinking half a glass of wine. Additionally, we found that a mutation in the cerebellar α6 subunit (α6R100Q), initially reported in rats selectively bred for increased alcohol sensitivity, is sufficient to produce increased alcohol-induced motor impairment and further increases of alcohol sensitivity in recombinant α6β3δ receptors. Furthermore, the behavioral alcohol antagonist Ro15-4513 blocks the low dose alcohol enhancement on α4/6/β3δ receptors, without reducing GABA-induced currents. In binding assays α4β3δ GABAARs bind [3H] Ro15-4513 with high affinity, and this binding is inhibited, in an apparently competitive fashion, by low ethanol concentrations, as well as analogs of Ro15-4513 that are active to antagonize ethanol or Ro15-4513’s block of ethanol. We conclude that most low to moderate dose alcohol effects are mediated by alcohol actions on alcohol/Ro15-4513 binding sites on GABAAR subtypes.
Ethanol (EtOH) is by far the most widely used and abused drug and EtOH-related accidents and other problems caused by alcohol abuse and addiction cause tremendous human suffering. On the other hand, there is increasing evidence that controlled low to moderate EtOH consumption has a number of long-term positive health implications. These potential beneficial alcohol effects include lower rates of myocardial infarction, reduced heart failure rate, lower risk for dementia, decreased risk of diabetes and reduced risk of osteoporosis (Pinder & Sandler, 2004; Standridge et al., 2004). Despite these important implications for human health and well-being, and despite a large effort of biomedical research dedicated to alcohol-related topics, our understanding of the molecular mechanisms of ethanol effects remains unclear (best illustrated by recent reviews: Criswell & Breese, 2005; Siggins et al., 2005; Weiner & Valenzuela, in press).
The view that EtOH and anesthetics act via modulation of fluidity of the lipid membrane of nerve cells with little or no specificity (Franks & Lieb, 1981; Suzdak et al., 1986a) has shifted to a protein/receptor based target with much emphasis on the GABA-mimetic actions of alcohol (Criswell & Breese, 2005) and direct actions of ethanol on GABAA receptors (GABAARs) (Korpi et al., 1998; Aguayo et al., 2002).
Because alcohol affects the brain only at grotesquely enormous concentrations (mM) compared to other drugs which usually act at much lower concentrations (nM–μM range) and due the inability to find receptors that respond to alcohol doses experienced during low to moderate drinking (around 1–20 mM blood alcohol level: the legal blood alcohol driving limit in most US states is 17.4 mM), it was assumed that effects of EtOH are caused by a summation of effects on a number of different receptors that are affected at doses much higher than those needed for light intoxication (e.g., after drinking half a glass of wine). Such high dose effects of alcohol have been studied extensively on a number of membrane proteins (and also soluble proteins like luciferase; Ueda & Suzuki, 1998) in recombinant systems and with electrophysiological studies in neurons and brain slices (for recent reviews, see Criswell & Breese, 2005; Siggins et al., 2005; Weiner & Valenzuela, in press).
It is not surprising that at doses between 30 mM and 300 mM, EtOH leads to measurable alterations in the functional properties of many proteins, including EtOH-induced changes in membrane properties that might indirectly alter the function of membrane receptors and channels. Furthermore, it is a leap to imply from the observation that EtOH affects some measurable parameter in an in vitro preparation and that these receptors must be important for in vivo EtOH effects. This is particularly true in many cases where anesthetic concentrations (≥50 mM) or even doses that are fatal in most humans (≥ 100 mM) were studied. Furthermore, in many studies of alcohol effects (in isolated neurons, brain slices, and in vivo in animals), the target proteins (alcohol receptors) that cause these phenomena are usually unknown; and because these systems are complex, data tend to be difficult to interpret.
Several systems have been proposed as final common pathways for alcohol effects that lead to alcohol intoxication and the hedonistic effects that may lead to alcohol addiction, but these must be triggered by the initial action at the actual (often unknown) alcohol target and so will not be considered further. These systems might include increased GABA release from nerve endings in appropriate circuits (Siggins et al., 2005) and G-protein coupled receptors pathways, in particular adenosine, β-adrenergic and GABAB receptors that have all been proposed to lead to changes in alcohol sensitivity (Proctor & Dunwiddie, 1984; Allan et al., 1991; Lee et al., 1995; Dar & Meng, 2004). The downstream effectors of these G-protein-coupled receptors could be related in function to effects on a common reward circuit that is activated by all drugs of abuse which seems to involve the cyclic AMP-mediated signaling pathway, in particular cAMP-activated protein kinase (Diamond & Gordon, 1997; Yao et al., 2003; Newton & Messing, 2006) and potential downstream effectors like CREB (Pandey et al., 2005) and DARPP-32 (Svenningsson et al., 2005).
Receptors and channels that have been shown to respond directly to alcohol include ionotropic glutamate receptors (GluR), potassium channels, calcium channels, adenosine receptors, as well as several members of the cys-loop superfamily of ligand-gated ion channels. One must ask if these candidate targets can qualify as relevant receptors for alcohol action by showing modulation in vitro in recombinant expression systems and in cells at concentrations achieved in brain after 1–2 glasses of wine (30 mM). Of course, many possible explanations exist for failure to show in vitro effects, such as lack of necessary accessory gene products in recombinant expression systems, for example, trafficking factors, scaffolding proteins, kinases (phosphorylation state), small molecule cofactors, etc. Plus, not all subtypes of these potential target proteins have been studied carefully.
Potassium channels represent legitimate candidates for alcohol receptors. The BK (big, Ca2+-dependent) K+ channels are enhanced by high concentrations of EtOH. In nematodes (C. elegans), alcohol is toxic and impairs locomotion; worms carrying a non-functional BK channel gene become resistant to this EtOH action, which occurs at a medium concentration between 100 mM and 500 mM, but an internal concentration claimed to be 20–40 mM (Davies et al., 2003). The G protein-coupled inwardly rectifying K+ channels, GIRK (Kobayashi et al., 1999; Lewohl et al., 1999), are enhanced by >10 mM EtOH. GIRK channel knock-out mice were shown to have diminished analgesic actions of EtOH (Blednov et al., 2003).
Ionotropic GluR, both NMDA (Lovinger et al., 1989) and non-NMDA (Woodward, 2000; Carta et al., 2003), have been reported to be inhibited by EtOH at relevant low concentrations. The partial NMDA receptor antagonism observed with ethanol in vitro is consistent with the action of the anesthetic ketamine on NMDA receptors at relevant anesthetic concentrations (Liu et al., 2006). However, the significance of NMDA and other GluR in mediating low dose EtOH effects remains to be established, particularly given that ethanol and ketamine have very different psychopharmacological actions (Morgan et al., 2004).
Virtually all the cys-loop ligand-gated ion channel receptors (LGIC) are modulated by ≥100 mM EtOH. These include receptors for serotonin, 5HT3 (enhanced (Lovinger & White, 1991), glycine (enhanced; Mihic et al., 1997; Lei et al., 2000; Aguayo et al., 2002; Roberto et al., 2003), nicotinic acetylcholine (nACh, inhibited; Forman & Miller, 1989) and GABAA (enhanced; Grobin et al., 1998; Aguayo et al., 2002). Because reconstituted recombinant receptors might not show the same alcohol sensitivity as native receptors in native neurons (due to, e.g., the lack of accessory proteins), it remains possible that these channels might mediate acute low dose EtOH effects. It is also possible that the cys-loop receptor family of ion channel proteins (which includes GABAA, glycine and nACh receptors) share common structural features, such as the water-filled pocket proposed for the low affinity alcohol/anesthetic sites at the extracellular end of the transmembrane domain (Yamakura et al., 2001), within one subunit or between subunits. Such a pocket could allosterically modulate channel kinetics, but due to the low energy involved in drug binding in this pocket, there is low potency and limited specificity for the modulators. This could be involved in the action of anesthetic levels (≥100 mM) but would not explain the action of ‘one glass of wine’ levels of alcohol.
While GABAARs have long been implicated in mediating alcohol actions in behavioral studies, the lack of direct alcohol effects at relevant low doses in many studies on synaptic GABAARs led to the view that alcohol must somehow indirectly increase GABAAR function in a GABA-mimetic manner, possibly involving increased GABA release (Breese et al., 2006), including mediatory and modulatory actions of neuroactive steroids (Morrow et al., 2001). However, we found in recombinant expression studies that some GABAARs possibly could account for the ‘one glass of wine’ receptor: only certain subtypes of GABAARs, those containing the β3 and δ subunits, were found to respond to EtOH with a threshold response of 3 mM when expressed in oocytes (Wallner et al., 2003). These δ subunit-containing GABAAR subtypes are present in the brain and show an extrasynaptic location. These GABAARs contribute to a persistent or tonic GABAergic inhibitory influence on neurons (Brickley et al., 1996) whose importance in setting the “overall” neuronal excitability has only fairly recently been recognized (Farrant & Nusser, 2005).
While it has been widely assumed that some GABAAR that mediate GABAergic synaptic transmission are sensitive to EtOH enhancement, this review focuses on the increasing evidence that the direct enhancement of nonsynaptic δ subunit-containing GABAAR may explain many of the acute low dose alcohol effects in our brain. The EtOH relevance has probably gone unnoticed because these types of receptors have not been much studied and are not very abundant. The development of the awareness of the physiological importance of these extrasynaptic receptors has coincided with the findings of their unique pharmacological properties, in particular their unique sensitivity to modulatory drugs, possibly due to a low GABA efficacy (despite high potency) (Bianchi & Macdonald, 2003; Wallner et al., 2003; Feng et al., 2004).
GABAARs have long been implicated in the intoxicating actions of alcohol because positive modulators of GABAARs such as barbiturates show striking similarities to alcohol in their effects on human behavior (Isbell et al., 1950). In addition, it was demonstrated that the GABAAR agonists (e.g., muscimol) potentiated the sedative properties of EtOH, while the opposite effect, a reduction of EtOH-produced sedation or motor-incoordinating effects, was seen upon administration of the GABAAR blocking agents picrotoxin and bicuculline (Hakkinen & Kulonen, 1976; Frye & Breese, 1982; Liljequist & Engel, 1982; Martz et al., 1983). Picrotoxin and bicuculline are not practical clinically as alcohol antagonists, because they lead to life-threatening convulsions. In addition, benzodiazepines also share similarities with EtOH action, and have additive, possibly even synergistic (super additive) effects, when taken together with EtOH (Hu et al., 1987; Tauber et al., 2003). Other GABAergic drugs show cross-tolerance and cross-dependence with EtOH, suggesting similar mechanisms (Khanna et al., 1998). Different strains of laboratory animals show variable sensitivity to EtOH and this correlates somewhat with barbiturates but very well with benzodiazepine sensitivity (Harris & Allan, 1989). This pharmacogenomic connection suggests a common brain pathway, if not receptor, for the actions of these drugs. In vitro studies supporting a GABA-mimetic action of EtOH, direct or indirect, are consistent with this notion (Breese et al., 2006).
Neuropharmacologists, early on, examined EtOH for effects on neurons in anesthetized animals or acute slices, and reported variable effects on nerve firing, excitatory or inhibitory transmission (Durand et al., 1981; Siggins et al., 1987; Deitrich et al., 1989; Lovinger et al., 1989; White et al., 1990; Narahashi et al., 1991; Morrisett & Swartzwelder, 1993). In some cases it was shown that GABA-mediated inhibitory currents in neurons are enhanced by relevant alcohol doses (Aguayo, 1990), or that there was at least a GABA-mimetic effect, which could be due to postsynaptic enhancement or increased presynaptic activity and/or release (Criswell & Breese, 2005; Siggins et al., 2005).
Using 36Cl− flux assays (Harris & Allan, 1985), a number of groups showed that EtOH at low millimolar concentrations increased Cl− flux in cell-free brain membrane homogenates (Suzdak et al., 1986b; Suzdak & Paul, 1987; Morrow et al., 1988).
What are the properties of these flux assays? The preparations were low-speed pellets, containing at least some synaptoneurosomes: these are pinched-off and resealed presynaptic nerve endings containing organelles and release apparatus, attached to postsynaptic cell membrane fragments in closed vesicular form that are capable of postsynaptic receptor-mediated ion flux. These preparations also include some synaptosomes (pinched off and resealed presynaptic nerve endings in closed vesicular form), which are unlikely to contribute to the flux signal through synaptic receptors because these receptors, in adhering fragments of postsynaptic membrane, are not attached to membrane-bound closed vesicular structures (Titulaer & Ghijsen, 1997). Membrane preparations used for 36Cl− flux assays also include nonsynaptic (resealed vesicular) plasma membranes containing extrasynaptic receptors that contribute to the flux signal. This 36Cl− flux is mediated by GABAARs as it can be increased by application of GABA or muscimol, and is inhibited by general GABAAR blockers like bicuculline and picrotoxin.
Particularly interesting is that the behavioral alcohol antagonist Ro15-4513 (a benzodiazepine) specifically blocked ethanol-induced synaptoneurosomal GABA/Cl− current increases (Suzdak et al., 1986a). Importantly, a parallel approach reported EtOH enhancement of GABAAR-mediated 36Cl− flux in intact cultured neuronal cells (Ticku et al., 1986), and this EtOH enhancement was inhibited by the benzodiazepine Ro15-4513 (Mehta & Ticku, 1988). These reports showed that GABAARs were targets of low dose EtOH, demonstrated in 2 different in vitro assays available at that time, despite controversial results from electrophysiology.
These cell-free neurochemical studies using 36Cl− flux assays in synaptoneurosome preparations provided strong evidence that EtOH at low intoxicating doses (3–30 mM) can stimulate Cl− flux through GABAARs. The fact that in some of these studies Cl− flux is detectable and can be stimulated by EtOH even without the addition of exogenous GABA to synaptoneurosomes (Suzdak et al., 1986a), suggests that this flux might be due to highly GABA-sensitive receptors that can respond to low endogenous GABA concentrations present in these preparations (DeLorey & Brown, 1992). In addition, these 36Cl− flux measurements have a fairly slow time resolution when compared to the ultrafast synaptic GABA events, suggesting that these synaptoneurosomal Cl− flux measurements might be preferentially due to the activity of highly ethanol-sensitive (possibly δ subunit-containing) GABAARs. Even without added GABA, synaptoneurosomal preparations may have contained at least 100 nM endogenous GABA, a GABA concentration sufficient to activate δ subunit-containing receptors, whereas the much less alcohol-sensitive γ2-containing receptors are likely to be functionally silent under these conditions because of their much lower GABA sensitivity and fast desensitization. It is perhaps not surprising that the results of such Cl− flux measurements vary, depending on the brain regions they are derived from, the age of the animals used, the exact protocol used to isolate the membrane fractions, the content of synaptoneurosomes, and the amount of concentrations of GABA or GABA agonists like muscimol added to measure EtOH stimulation. Difficulties in the reproducibility of low dose ethanol enhancement in these Cl− flux assays in different laboratories (Uusi-Oukari & Korpi, 1989; Mihic et al., 1992) might have raised skepticism concerning the validity of these data to explain low dose alcohol effects on GABAARs. In addition, synaptic physiologists might have considered the conditions under which 36Cl− flux assays are performed non-physiologically, but they do make sense when considering that continuously active, highly GABA-sensitive GABAARs (like those containing the δ subunit) were measured under these experimental conditions.
There are reports that showed that under certain conditions GABAARs can be activated by low (<30 mM) relevant EtOH concentrations in isolated and cultured neurons. For example, Aguayo (1990) showed that low concentrations of EtOH can increase the GABA current evoked by 2.5 μM GABA, a minimally desensitizing concentration in cultured hippocampal as well as cerebral cortical neurons. However, this effect was seen only in a fraction (up to 50%) of neurons and it was reported that the increase in EtOH enhancement diminished when the GABA concentration was raised. This is consistent with the notion that the activation of abundant, but EtOH-insensitive, synaptic GABAARs obscures or dilutes the EtOH enhancement when higher GABA concentrations (>3 μM) are applied to these neurons. In addition, the age of the culture could be important, consistent with the finding that GABAAR δ subunits are only expressed at the latter stages of development (Aguayo et al., 2002). Fig. 1 shows GABA current recordings (evoked by application of 2.5 μM GABA) from an EtOH-sensitive and an EtOH-insensitive neuron (reproduced from Aguayo, 1990). Similar low dose alcohol effects on isolated neurons from several brain regions and species were also reported by Reynolds et al. (1992) who showed that low (1–50 mM) EtOH concentrations produced an enhancement of I-GABA, evoked by local low concentration GABA application to the cell soma by brief pressure pulses, in a large fraction of neurons (~50% in rat, mouse and chick cerebral cortex).
Despite the fact that there was considerable variability and not all neurons are responsive to low dose EtOH, the abovementioned findings clearly implicated GABAARs as potential sites for EtOH actions. However, as electrophysiological methods became more sophisticated and researchers gained the ability to record synaptic events of connected neurons in brain slice preparations, most studies showed that individual GABAergic synaptic events are not enhanced by relevant EtOH concentrations, which eventually lead researchers to question the role of postsynaptic GABAAR as direct EtOH targets (Breese et al., 2006; Weiner & Valenzuela, in press). However, given that there are many different synapses, the situation is almost certainly complex; and it has been shown that under certain conditions and in certain locations synaptic GABAARs can be sensitive to low relevant EtOH concentrations (Wan et al., 1996; Weiner et al., 1997; reviewed by Weiner & Valenzuela, in press). Particularly interesting in this context is a recent report that chronic intermittent EtOH treatment leads to a decrease in extrasynaptic GABAAR responsiveness to ETOH, whereas synaptic receptors become more sensitive to EtOH (Liang et al., 2006).
In some brain regions, for example cerebellar Purkinje cells, EtOH at relevant pharmacological doses decreases excitability, which was demonstrated to be related to an increase in GABA-mediated inhibition, leading to reduced firing rates of cerebellar Purkinje cells (Palmer & Hoffer, 1990; Weiner & Valenzuela, in press). A popular candidate of EtOH target was the β-adrenergic signaling pathway, because EtOH enhanced GABAAR-mediated inhibition of cell firing by norepinephrine (Smith et al., 1987). Potentiation by EtOH of inhibitory synapses in brain slices was observed, but only under certain prescribed conditions, conditions which varied from one laboratory to another, such as how the slices were treated or what drugs were utilized (Wan et al., 1996; Weiner et al., 1997; Roberto et al., 2003). Numerous negative reports of EtOH–GABA interactions complicated the picture, and most of the positive effects could be interpreted as indirect.
The inability to observe reproducible low dose EtOH enhancement of GABAAR currents was suggested to involve either (1) a highly subunit-selective GABAARs that varied with cells and therefore assays and investigators; or (2) an indirect effect on GABAARs where the actual EtOH receptor was some other protein that directly or indirectly modulates GABAAR function (Newton & Messing, 2006). The indirect modulation might involve protein phosphorylation, either of GABAAR protein or another protein (Harris et al., 1995). The first possibility was supported by the ‘γ2L subunit’ hypothesis (Wafford et al., 1991), which is now considered unlikely (Sigel et al., 1993; Marszalec et al., 1994; Homanics et al., 1999; Wallner et al., 2003). The second hypothesis was also potentially related to the γ2L splice variant, since it differed from γ2S having added an 8-amino acid insert containing a protein kinase C (PKC) substrate site. Wafford and Whiting showed that the proposed greater ethanol sensitivity of the γ2L subunit was abolished (in α2β2γ2LS343A receptors) by the γ2LS343A mutation that removed this PKC phosphorylation site (Wafford & Whiting, 1992). Others suggested that PKC isoforms (Weiner et al., 1994; Harris et al., 1995; Hodge et al., 1999; Olive & Hodge, 2000; Proctor et al., 2003) modulated EtOH sensitivity of GABAARs, depending on the subtype of PKC (Boehm et al., 2004), but probably by acting on other proteins, possibly related to presynaptic effects on GABA release, or postsynaptic effects on receptor density and/or trafficking.
Nevertheless, as evidence mounted for general anesthetic enhancement of GABAAR function, long chain alcohol anesthetics like n-octanol were among the agents shown to be active (Wick et al., 1998). The potency was related to the chain length (and lipid solubility, cf. Meyer-Overton), that is, octanol was more potent than hexanol, and hexanol was more potent than butanol. It followed that ethanol would also be active, but only at very high doses, like 0.1–1.0 M, and probably is fatal to organisms (Nakahiro et al., 1991; Narahashi et al., 1992). The exact sensitivity could and probably did vary with the subunit composition of the GABAAR, but effects at relevant (≤ 30 mM) ethanol concentrations were highly controversial as they were not found in all neurons studied (Breese et al., 1993). It is interesting that almost all of these workers cited in this section (and many others) at one time or another took an anti-GABAAR view of alcohol acute actions, and later supported such a connection. However, many of these positive observations involved high (≥100 mM) doses. One difference between EtOH and general anesthetics was the lack of readily reproducible effect of EtOH on ligand (e.g., GABA, benzodiazepine, or convulsant) binding in vitro, as opposed to anesthetics, where agents that enhance function (Cl− flux or electrophysiology) also modulate binding (Olsen et al., 1991).
Recombinant GABAARs are enhanced by EtOH concentrations ≥100 mM, mediated through a potential EtOH “site” within the membrane-spanning parts of the receptor (Mihic et al., 1997) which is also important for anesthetic effects of etomidate and propofol. However, recombinant GABAARs sensitive to relevant intoxicating concentrations of EtOH (3–30 mM) have been identified only very recently (Sundstrom-Poromaa et al., 2002; Wallner et al., 2003), and both of these studies show that the presence of the δ subunit (presumably in place of the γ2 subunit) is necessary for highly EtOH-sensitive receptors. In our hands both δ and β3 subunits are necessary to produce GABAAR subtypes that are sensitive to low millimolar EtOH (Fig. 2A)(Wallner et al., 2003; Hanchar et al., 2004).
δ subunit-containing GABAARs have been shown to be excluded from GABAergic synapses (Nusser et al., 1998; Wei et al., 2003) and are activated by ambient extracellular GABA concentrations (Brickley et al., 1996; Mody, 2001) in the order of 0.3–1 μM (DeLorey & Brown, 1992; Mody, 2001). Recombinant receptors containing the δ subunit and tonic currents mediated by these GABAAR are also highly sensitive to allosteric modulators (Brown et al., 2002; Wohlfarth et al., 2002) including steroids, anesthetics, and EtOH. Recordings of tonic currents in dentate gyrus granule cells (with a likely subunit composition of α4β3δ subunits) and in cerebellar granule cells (α6β3δ) confirm the high neurosteroid and EtOH sensitivity seen with recombinant receptors (Stell et al., 2003; Carta et al., 2004; Wei et al., 2004; Hanchar et al., 2005; Liang et al., 2006).
The failure to see low (relevant concentration, <30 mM) EtOH effects on GABAARs in more recent studies is probably due to the fact that these studies focused on recombinant receptors containing γ2 subunits and the more abundant synaptic GABAARs in slices and cultured neurons, although as discussed above, it remains possible that under certain conditions synaptic GABAAR subtypes are sensitive to relevant EtOH concentrations and might contribute to behavioral EtOH effects.
Besides showing increased GABA sensitivity and slower desensitization, δ subunit-containing GABAARs have another striking feature that distinguishes these receptors from the synaptic γ2-containing receptors. In recombinant systems these receptors (even at saturating GABA concentrations) can be dramatically enhanced by drugs like barbiturates, neurosteroids and etomidate and propofol, suggesting that the open probability of these receptors even at receptors fully occupied by GABA is low: in other words, GABA is only a partial agonist at these receptors (Wohlfarth et al., 2002; Bianchi & Macdonald, 2003; Wallner et al., 2003; Feng et al., 2004). It is tempting to suggest that these anesthetic drugs might act by converting GABA from a partial agonist into a full agonist and it is this action that leads to a dramatic decrease of neuronal activity leading to anesthesia. Fully consistent with this notion is our finding that tonic currents in cerebellar granule cells are highly sensitive to EtOH and therefore must contain the β3 subunit, and that the β3 subunit-containing receptors mediate the in vivo anesthetic effects of etomidate and propofol because a point mutation in the β3 subunit (N265M) that eliminates etomidate and propofol effects on recombinant receptors in knock-in mice essentially eliminates etomidate and propofol anesthetic effects (Jurd et al., 2003). In contrast, a similar mutation in the β2 subunit (β2N265S) only eliminates the sedative “side” effects of etomidate and propofol but not the anesthetic effects (Reynolds et al., 2003). Therefore it is tempting to speculate that the β3 selectivity of these GABA-anesthetic drugs could be due to the fact that in many brain regions δ subunit-containing receptors are associated with the β3 subunit (although there are exceptions, e.g., the thalamus expresses only low amounts of the β3 subunit and the abundant δ likely is paired with α4β2; Sieghart & Sperk, 2002). Mutations at the β3N265M homologous residues in transmembrane region 2 of GABAR subunits have been shown to eliminate the high dose (≥100 mM) “anesthetic” ethanol effects on certain types of GABA receptors (Mihic, 1999). It therefore will be interesting to study if and to what extent existing β3N265M and the β2N265S knock-in mice would differ in their alcohol sensitivity at high and low doses of alcohol.
While many of the details on the molecular mechanisms of how EtOH modulates, how much and at what EtOH concentrations these specialized type of GABAAR receptors contribute to acute alcohol effects, and how tolerance and addiction affect these receptors remain open; the identification of α4/6β3δ subunit-containing receptors together with reports that at the same concentrations EtOH enhances tonic currents suggest that these functionally unique types of GABA receptors are important direct alcohol targets.
Researchers discovered more evidence for GABAAR involvement in the intoxicating actions of EtOH when selectively outbred rat lines were shown to differ in their motor-impairment response to both benzodiazepines and EtOH (Hellevuo et al., 1989). These rat lines were segregated (by selective breeding over many generations) into 2 groups, EtOH-sensitive (alcohol non-tolerant, ANT) and EtOH-insensitive (alcohol tolerant, AT) (Eriksson, 1990). They were selected in a way that was not based on any differences in alcohol metabolism, largely determined by levels and isoforms of the alcohol dehydrogenase enzymes (for reviews, see Ehrig et al., 1990; Ramchandani et al., 2001). These AT and ANT animals were selected (in about 30 generations) on a tilting plane, a task that tested the motor performance of these animals to rapidly adjust their body posture to resist sliding down on a rough surfaced plane, raised at a constant speed (Eriksson, 1990).
It was reported that the ANT rats lost most of the diazepam-insensitive cerebellar [3H]Ro15-4513 binding, that is, [3H] Ro15-4513 binding in the presence of ≥10 μM cold diazepam (Uusi-Oukari & Korpi, 1990; Uusi-Oukari & Korpi, 1991). The reason for this pharmacological change was shown to be a ‘point mutation’ (polymorphism) in the “benzodiazepine site” α6(R100Q) of the cerebellar GABAAR α6 subunit (Korpi et al., 1993; Korpi & Seeburg, 1993). The α6R100Q point mutation makes α6-containing receptors, when expressed with β2 and γ2 subunits, diazepam-sensitive (wild-type α6β2γ2-containing receptors are insensitive to classical BZ agonists like diazepam), thus providing an explanation not only for the changes in Ro15-4513 pharmacology but also for the increased behavioral benzodiazepine sensitivity of these ANT rats. However, because of the lack of EtOH effects with the α6(R100Q) mutant in recombinant systems (when expressed with β2 and γ2), it was speculated that alterations in genes other than α6 (but cosegregating with it) might be responsible for the high EtOH sensitivity of these animals (Farrant & Cull-Candy, 1993; Korpi et al., 1993).
The same α6(R100Q) polymorphism has also been found enriched in the independently derived “Sardinian alcohol non-preferring sNP” rats (Saba et al., 2001; Sanna et al., 2003), a rat line that was segregated from Sardinian alcohol preferring rats (sP) based on their voluntary alcohol consumption. The identification of the same “mutation” occurring in 2 different rat lines is likely due to the selection of a fairly frequent naturally occurring α6(100Q) allele. The fact that the published rat genomic sequence is the α6-100Q allele is fully consistent with this notion. However, the α6-100Q allele has not been found in certain rat strains, consistent with the observation that rat lines selected from these strains for differences in alcohol preference only carry the α6-100R WT allele (Carr et al., 2003) and most rat and mouse lines selectively bred for differences in alcohol sensitivity also do not show changes in diazepam-insensitive [3H]Ro15-4513 binding in the cerebellum (Uusi-Oukari & Korpi, 1991).
The selective breeding in the ANT/AT animals led to an almost complete separation of WT (α6-100R) and (α6-100Q) alleles, supporting the notion that the α6-100Q allele makes an important contribution to the increased alcohol-induced motor incoordination in ANT rats. In contrast, the α6-100Q allele is only enriched in the alcohol non-preferring animals (Saba et al., 2001), indicating that the α6-100Q allele might contribute to the alcohol non-preference, but its relative importance is lower when compared to other genes, yet to be identified, which contribute to alcohol preference in these animals.
It was found that cerebellar granule cells, the only abundant neuron that expresses the α6 subunit, also has high levels of δ and β3 subunit protein (Pirker et al., 2000) (see Fig. 5). Therefore cerebellar granule cells express all subunits required to make highly alcohol-sensitive receptors in recombinant expression (Wallner et al., 2003). We showed that the α6-R100Q when expressed with β3 and δ subunits led to a further increase of the already high alcohol sensitivity of recombinant α6β3δ receptors (Hanchar et al., 2005), thereby providing the molecular basis of the increased alcohol sensitivity of ANT animals (Fig. 2A). In addition, we found, consistent with the notion that the α6-R100Q allele is frequent in certain rat lines, that in Sprague-Dawley laboratory rats (supplied by Charles Rivers) the α6R100Q “mutation” is a frequently-occurring allele (a naturally occurring knock-in point mutation). We used these animals to show that the α6-100Q allele is sufficient for increased sensitivity to the motor-incoordinating effects of EtOH. The increased EtOH-impairment in α6-100QQ rats is particularly pronounced at the lowest alcohol dose (0.75 g/kg) where only the α6-100Q mutant animals show a decrease in motor performance on the rotarod (Fig. 2B). In addition, we showed that tonic currents in cerebellar granule cells in slices from homozygous α6-100QQ animals show increased EtOH sensitivity relative to α6-100R/R animals (Hanchar et al., 2005) (Fig. 2C).
One report that tonic GABA currents in cerebellar granule cells can be enhanced by low concentrations of EtOH has been interpreted as being caused by an increase in presynaptic GABA release, because the increase in tonic GABA currents produced by EtOH is accompanied by an increase in firing frequency (Carta et al., 2004). In the Carta et al. study, ethanol-induced increases in tonic GABA current are abolished by the sodium channel blocker tetrodotoxin (TTX) that also blocks all GABA releases (except for rare spontaneous release events). We showed that if GABA is replenished in the slice preparation by adding 300 nM GABA, TTX (1 μM) does not block ethanol enhancement (Hanchar et al., 2005). In addition, α6-100QQ homozygous rats show not only dramatically increased EtOH sensitivity of tonic currents but also show a higher EtOH-induced increase in firing frequency of cerebellar granule cells. Because the α6 subunit is exclusively expressed in cerebellar granule cells, and the changes are associated with the genotype (increased firing frequency in the alcohol hypersensitive α6-100QQ rats), we suggested that alcohol effects on extrasynaptic α6-containing GABAARs cause the increased firing frequency. In other words, the increased firing of Golgi interneurons observed with ethanol is likely due to network properties, involving circuits preserved in the cerebellar slice preparation (Hanchar et al., 2005). The same group that reported that TTX blocked EtOH enhancement of tonic currents in cerebellar granule cells (to support their hypothesis of a presynaptic EtOH effect) also did not find increased EtOH sensitivity of tonic currents using inbred ANT and AT rats, homozygous for the α6-100Q and α6-100R alleles, respectively (Valenzuela et al., 2005; see response by Otis et al., 2005).
While we think that positive results by our group and others demonstrate the importance of tonic GABA receptors in EtOH sensitivity, there have been negative results that are in apparent contradiction to the finding that the α6-100Q allele leads to alcohol hypersensitivity. One of these is the observation that α6 knock-out animals do not show changes in EtOH sensitivity (Homanics et al., 1997b), and the other is that backcrosses of ANT/AT animals did not show a segregation of the EtOH-sensitive phenotype with the mutant α6 alleles (Korpi et al., 1992; Radcliffe et al., 2004). We think that a possible, maybe even likely, explanation is differences in the EtOH doses at which behavioral assays for alcohol intoxications are performed. With the α6-100Q naturally occurring knock-in point mutation, the most dramatic difference was at the lowest alcohol dose of 0.75 g/kg (where only the α6-100QQ animals show alcohol-induced motor impairment, Fig. 3B), no significant differences were detected at doses ≥1.75 g/kg EtOH i.p. This is unexpected because the initial motor-incoordination selection to generate the ANT/AT animals was done at an EtOH dose of 2 g/kg i.p. (Eriksson, 1990). During the 30 generations of selection to generate the AT/ANT lines, other changes might have been selected that allowed the penetrance of the α6-100Q EtOH-supersensitive phenotype. Such additional factors that allowed the penetrance of the α6 phenotype at the 2 g/kg dose might have been lost during backcrossing. Similarly, α6 total knock-out animals have only been tested at fairly high EtOH doses (Homanics et al., 1997b), where no difference in the α6-100Q natural knock-in was seen, and it remains to be determined if a careful study of lower alcohol doses might reveal a slightly diminished alcohol sensitivity in motor-coordination tests in the α6 total knock-outs.
In summary, these findings on the α6-R100Q alcohol-supersensitive mutation provide the first evidence that links EtOH-sensitive extrasynaptic δ subunit-containing GABA receptors and tonic GABA currents to the behavioral actions of EtOH.
Because the pharmacological profile of EtOH bears many similarities to that of benzodiazepines and barbiturates (discussed in Section 2.1), Hoffmann-LaRoche scientists routinely tested newly synthesized benzodiazepines for their interaction with EtOH and barbiturates. While most classical BZ agonists enhance EtOH effects (in an additive or maybe even synergistic manner), the imidazobenzodiazepine Ro15-4513 blocked behavioral actions of EtOH without affecting EtOH metabolism or blood EtOH levels, without obvious behavioral effects in rats by itself (up to 10 mg/kg) (Bonetti et al., 1985; Polc, 1985).
The EtOH antagonist effect of Ro15-4513 is stunning: at a dose of 2 g/kg EtOH that leads to severe intoxication with ataxia and heavy sedation in rats, most animals are rescued from any signs of visible intoxication by 3 mg/kg Ro15-4513 (Suzdak et al., 1986a). A number of detailed studies by different groups showed that Ro15-4513 prevented the increased exploration and locomotion at very low EtOH doses (0.25, 0.5 and 0.75 g/kg in rats) (June & Lewis, 1994), the anxiolytic effects at low doses (1 g/kg in rats) (Suzdak et al., 1986a; Glowa et al., 1988; Becker & Hale, 1991) the sedative, motor impairing, as well as amnestic effects at moderate EtOH doses (2 g/kg rats or mice) (Suzdak et al., 1986a; Bonetti et al., 1988; Nabeshima et al., 1988; Dar, 1995), as well as the anticonvulsant (seizure protective) effects of EtOH (2 g/kg) against bicuculline and picrotoxin-induced convulsions (Kulkarni & Ticku, 1989). In addition, the observation that Ro15-4513 reduces EtOH self-administration (June et al., 1991; Rassnick et al., 1993; Petry, 1995) suggests that the rewarding effects of EtOH might be mediated by EtOH/Ro15-4513-sensitive GABAAR. However, Ro15-4513 does not prevent all EtOH effects: at higher EtOH doses (≥2 g/kg in rats), Ro15-4513 significantly reduces, but does not prevent the anesthetic (“sleep”-inducing) effects of EtOH (Marrosu et al., 1989), and Ro15-4513 does not prevent the hypothermic effects of EtOH (Hoffman et al., 1987; Syapin et al., 1987), consistent with the notion that part of the hypothermic (and analgesic) EtOH actions are mediated by other targets, possibly GIRK K+ channels (Blednov et al., 2003; Costa et al., 2005). In addition, it was shown that Ro15-4513 provided only limited protection to lethal effects at massive EtOH doses (Kolata, 1986; Lister & Nutt, 1987; Marrosu et al., 1989). Because of Ro15-4513’s limited ability to reverse lethal EtOH effects and because of the legal implications of having a drug blocking EtOH actions without actually lowering blood EtOH levels, Hoffmann-LaRoche decided not to pursue EtOH antagonist benzodiazepines for commercialization (Kolata, 1986). In addition, there were studies that showed that Ro15-4513 can trigger tremors in squirrel monkeys (Miczek & Weerts, 1987) and that it has proconvulsive properties in rodents, in particular at high doses; these effects are probably mediated by the weak inverse agonist activity on certain types of GABAAR (Lister & Nutt, 1987).
Ro15-4513 is the azido analog of the benzodiazepine receptor antagonist flumazenil (a.k.a. Ro15-1788), now used in the clinic to reverse benzodiazepine effects and overdoses. Despite the structural similarity with Ro15-4513, flumazenil is completely ineffective as an acute EtOH antagonist and when given together with Ro15-4513 prevents EtOH antagonism. The feature of flumazenil to antagonize Ro15-4513’s EtOH antagonistic effects is shared by the BZ-site ligands β-CCE, FG7142 and CGS-8216 (Suzdak et al., 1986a; Glowa et al., 1988). The observation that the more efficacious inverse agonists β-CCE and FG7142 at low doses did not only lead to EtOH antagonism but were shown to prevent the EtOH antagonist action of Ro15-4513 argued against the notion that it is the weak inverse agonist activity of Ro15-4513 on certain types of GABAARs that explains the behavioral EtOH antagonism. However, the inverse agonist action of Ro15-4513 may explain why in some studies Ro15-4513 was reported to diminish barbiturate effects (for review, see Lister & Nutt, 1987), although the barbiturate antagonism was not seen in all studies (Suzdak et al., 1986a). In some behavioral studies FG7142 was also reported to reverse EtOH effects, although only at doses far higher than those required for Ro15-4513 (Lister, 1987; Ticku & Kulkarni, 1988; Kulkarni & Ticku, 1989).
As discussed above (see Sections 2.3 and 2.4), under conditions that favor the detection of highly GABA sensitive receptors, the activity of GABAAR was shown to be enhanced by low EtOH concentrations. Suzdak et al. (1986a) were the first to show that this low dose of EtOH enhancement observed in 36Cl− flux assays in synaptoneurosomes is abolished by the behavioral alcohol antagonist Ro15-4513 in a dose-dependent manner, with a complete block of 50 mM EtOH effects with 100 nM Ro15-4513 (Fig. 3A). Furthermore, it was demonstrated that the low dose ethanol enhancement of GABA currents in neurons, seen under experimental conditions that preferentially activated highly GABA-sensitive tonic currents (discussed above), are reversed by 100 nM Ro15-4513 (Reynolds et al., 1992) (see Fig. 3B). In addition, other reports found that the decrease in spontaneous neuronal firing frequency by relevant doses of EtOH, seen in many neuronal cell types, is reversed by Ro15-4513 (Palmer et al., 1988; Marrosu et al., 1989).
We found that 100 nM Ro15-4513 also blocks in the EtOH augmentation on recombinant α4/6β3δ GABAAR. Fig. 3C shows a representative recording demonstrating that the enhancement of recombinant α4β3δ GABAAR by 30 mM EtOH is blocked by 100 nM Ro15-4513. At this Ro15-4513 concentration, Ro15-4513 has no effect on the GABA-induced current; that is, it specifically blocks the low concentration alcohol enhancement. The alcohol antagonist action of Ro15-4513 on α4β3δ GABAARs is reversed by flumazenil and β-CCE, 2 compounds that have been previously reported to also reverse Ro15-4513’s alcohol antagonism in behavioral studies (Suzdak et al., 1986a; Glowa et al., 1988). Therefore we can mirror the behavioral alcohol antagonist effects of Ro15-4513, including the reversal of Ro15-4513’s alcohol antagonism by flumazenil and β-CCE on recombinant α4/6β3δ subunit-containing receptors (Fig. 3C).
As expected from the alcohol antagonism of Ro15-4513 on δ subunit-containing receptors, we showed that native and recombinant α4/6β3δ GABAAR have a high affinity [3H]Ro15-4513 binding site (Hanchar et al., 2006). [3H]Ro15-4513 (but not [3H]flumazenil) binding to native (immunopurified from cerebellum) and recombinant δ subunit-containing (α4β3δ) GABAAR (not the binding of [3H]Ro15-4513 to the classical BZ site) is inhibited by low millimolar concentrations of EtOH (Fig. 4A) in an apparently competitive manner. It seems likely that the unique azido group of Ro15-4513 (fluorine in flumazenil) is the moiety that competes with EtOH for the same binding pocket. Consistent with this view are 2 recent reports of behavioral EtOH antagonist activity of Ro15-4513/flumazenil congeners named RY024 and RY023, that have a cyano- or an acetylene – instead of an azido – group at the C7 position of the BZ ring (McKay et al., 2004; Cook et al., 2005). In addition, it has been shown that the C7 position in classical benzodiazepines is close to the a critical histidine residue in GABAAR α1,2,3,5 subunits (α1-H101) (Berezhnoy et al., 2004) that is required for sensitivity of GABAAR to classical benzodiazepines in vitro (Wieland et al., 1992; Benson et al., 1998) and in vivo (Rudolph et al., 1999) and photolabeled by [3H]flunitrazepam (Duncalfe et al., 1996). The residue homologous to this histidine is an arginine (R100) in α4 and α6 GABAAR subunits, and as described above in Section 2.5, leads to increased EtOH sensitivity of β3 and δ subunit-containing receptors in vivo and in vitro (Hanchar et al., 2005). It therefore seems likely that the α4/6-100R/Q residue is critical for alcohol sensitivity because it is close to, and might even directly line, the EtOH binding site on these subtypes of GABAARs.
Furthermore, we show that binding of the EtOH antagonist [3H]Ro15-4513 is also inhibited by BZ site ligands (FG7142, β-CCE) that have been previously shown to inhibit Ro15-4513’s EtOH antagonist action (Hanchar et al., 2006) (see Fig. 4B). This [3H]Ro15-4513 site in δ subunit-containing GABAARs has not been found previously, likely because it is insensitive to the classical BZ site ligands like diazepam and flunitrazepam. In addition, α4/6β3δ receptors are of relatively low abundance and binding of the high affinity ligands Ro15-4513 and flumazenil to these GABAAR subtypes is functionally silent, except under special circumstances, that is, in the presence of EtOH enhanced receptors, and therefore remain usually undetected in functional assays. Consistent with the low abundance of δ subunit-containing receptors we show that only a small fraction, ~6% of total [3H]Ro15-4513 binding in the cerebellum, is inhibited by low doses of EtOH (Hanchar et al., 2006).
At EtOH concentrations exceeding 30 mM there is a component of the EtOH enhancement in α4β3δ GABAARs that is resistant to Ro15-4513 block, but this is eliminated by a mutation in the β3 subunit (β3-N265M) (Wallner et al., 2006). Receptors composed of α4β3N265Mδ have a saturable EtOH dose–response curve, with a half maximal response at 16 mM (Wallner et al., 2006). The β3N265M mutation has been previously shown to eliminate high dose EtOH (200 mM) effects on recombinant GABAAR (Mihic et al., 1997). Therefore, GABAARs have 2 distinct EtOH sites, a site in the transmembrane region that might contribute to the very high dose anesthetic alcohol effects and a “high affinity” site at certain subtypes of GABAARs that is blocked by the behavioral alcohol antagonist Ro15-4513.
We conclude that GABAARs that carry EtOHl/Ro15-4513 binding sites are important mediators of behavioral effects in mammalian brains.
GABAAR subtypes containing the δ subunit, in vivo most frequently associated with α4or α6 subunits, show an extra- or perisynaptic location and unique physiology and pharmacology. These receptors mediate tonic currents in vivo, and in recombinant systems when expressed with the β3 subunit are sensitive to EtOH concentrations that mirror the blood alcohol concentrations achieved during low and moderate ethanol consumption. These highly EtOH-sensitive receptors are positioned in the CNS appropriately to account for many of the acute effects of EtOH achieved by blood levels during social drinking. Fig. 5 shows the distribution of GABAAR subunits in rat brain that are required to make the ‘one glass of wine’ receptors in the brain (Pirker et al., 2000; Peng et al., 2002). Note a significant level of all 3 subunits, α4, β3, and δ, in the dentate gyrus, frontal cortex, parts of the neostriatum, and other forebrain nuclei.
If these GABAARs mediate low dose ethanol effects, the behaviors affected would involve circuitry in which these GABAARs are major participants, a testable hypothesis. In fact we show that a mutation in the α6 subunit, highly and almost exclusively expressed in cerebellar granule cells, is responsible for increased alcohol-induced motor impairment in animals that carry this mutation. Receptors formed by α4, β3 and δ subunits are found in regions of the brain where they are likely to mediate the amnestic (hippocampus), the sedative, anxiolytic and possibly also the rewarding effects of EtOH. Sedation, relief of anxiety, amnesia, motor impairment and rewarding effects are modalities of ethanol intoxication that have been reported to be reversed by the alcohol antagonist Ro15-4513 in behavioral studies.
The rat single nucleotide genetic variant in the GABAAR α6 subunit (α6100Q), showing supersensitivity to EtOH, leads to 2 important implications: (a) it demonstrates the in vivo relevance of the newly discovered low dose EtOH-sensitive GABAAR: extrasynaptic GABAAR can serve as the ‘one glass of wine receptors’ in brain; and (b) it provides a possible biochemical insight into the actual EtOH binding site: a ‘benzodiazepine site’ in the extracellular domain of the GABAAR protein might be involved in EtOH modulation. This led to our discovery that the in vivo EtOH antagonist action of the benzodiazepine Ro15-4513 is due to its specific block of the EtOH enhancement on subtypes of GABAARs (like those containing the δ subunit), consistent with their role in low dose EtOH effects. These GABAAR subtype proteins appear to have a specific site of EtOH interaction at subunit interfaces in the extracellular domain that allow a potent and efficacious modulation by EtOH. The sites most sensitive to the modulation by EtOH are not, like those of most general anesthetics, in the trans-membrane domains, but like BZ, in the extracellular domain in modified GABA agonist sites, but only on certain subtypes of GABAARs. It remains possible that similar EtOH modulation sites of high potency or efficacy will be found on other types of GABAARs or other receptor channels. For the moment, several observations are consistent with the new idea that certain subtypes of GABAARs are indeed acting as the pharmacologically relevant EtOH receptors.
To confirm that subtypes of GABAARs do indeed mediate EtOH effects, there is a need for either knock-out animals or knock-in point mutations. However, results obtained from knock-out animals can be complicated (and sometimes even misleading) as these animals lack gene products of interest during their ontogenesis, and this often leads to compensatory changes. Probably the most impressive example is the comparison of β3 knock-out mice with mice that carry a single point mutation (GABAAR-β3N265M). It is difficult to understand how the total knock-out could show a much less pronounced phenotype (Homanics et al., 1997a) in terms of reduced etomidate/propofol sensitivity than a mouse that carries only a single β3N265M point mutation in the second transmembrane region (Jurd et al., 2003). Another example is our finding that the α6-R100Q polymorphism increases the EtOH-induced motor coordination in rats, whereas no changes in EtOH sensitivity have been reported for the α6 total knock-out mouse, with the assays and EtOH doses employed to date (Homanics et al., 1999). It remains possible that effects of lower doses of EtOH might be more likely to show changes in behavior.
However, we do not think that knock-out data are not valuable (Olsen & Homanics, 2000). Hopefully, with a better understanding of physiology and pharmacology of EtOH effects on GABAARs we should be able to eventually understand why δ knock-out animals differ in certain, but not all aspects of EtOH sensitivity (Mihalek et al., 2001). The seizure protective effect of EtOH at a moderately intoxicating dose (2 g/kg IP) is completely missing in the δ subunit knock-out animals (Mihalek et al., 2001, Fig. 3)(δ−/− animals show increased bicuculline-induced seizure threshold vs. wild type, and this is not further altered by 2 g/kg EtOH). Also, δ−/− animals show reduced voluntary EtOH consumption, consistent with the observation that Ro15-4513 reduces EtOH self-administration. Also consistent with the finding that Ro15-4513 does not reverse the hypothermic EtOH effect is that δ subunit ablation has no effect on hypothermic EtOH effects. In addition, consistent with the notion that “anesthetic” EtOH effects are primarily mediated by Ro15-4513-insensitive EtOH actions, there is little or no genotype effect on “sleep time” at a dose of 3.5 g/kg in the δ subunit knock-out mice or the α6-100Q (natural polymorphism) rat mutants.
While it was reported that δ knock-out animals do not differ in rotarod performance from WT mice, the effects of ethanol on δ−/− and δ+/+ mice were not reported. However, it was reported that there is no change in anxiolytic activity of EtOH in the elevated plus-maze test (Mihalek et al., 2001). Because it has been found that anxiolytic EtOH effects can be reversed by Ro15-4513 (e.g.,Suzdak et al., 1986a), this could be an indication that there may be additional, possibly non-δ-containing subtypes of GABAARthat may carry Ro15-4513-sensitive EtOH sites. Particularly α2 subunit-containing GABAARs may be good candidates for mediating anxiolytic EtOH effects (Low et al., 2000).
To confirm that subtypes of GABAARs are mediators of ethanol effects it will be important in the future to investigate mice that either have a GABAAR α4 subunit total knock-out or knock-in point mutations (e.g., α4-R100Q) that are expected to change the alcohol sensitivity of abundant Ro15-4513/ethanol sensitive GABAAR subtypes. Behavioral alcohol antagonists like Ro15-4513, in particular alcohol antagonists that lack the intrinsic inverse agonist activity of Ro15-4513, would be valuable tools to dissect alcohol effects that are mediated by the EtOH/Ro15-4513 site and clearly distinguish them from effects on other acute alcohol targets.
In addition, targeting of the alcohol site by certain benzodiazepine site ligands not only opens the possibility to identify the ethanol/Ro15-4513 binding site, but also to develop drugs that target the EtOH/Ro15-4513 site on GABAARs. Such drugs might be useful as alcohol antidotes as well as alcohol mimetics in the clinic. “Alcohol mimetics” (synthetic alcohol-site agonists) may be able to harness certain aspects of acute as well as long-term beneficial alcohol actions for therapeutic purposes.
This work was supported by a NIH pre-doctoral fellowship AA015460 to H.J.H., an Alcoholic Beverage Medical Research Foundation grant to M.W., NIH grants NS35985 and AA07680 and funds provided by the State of California for medical research on alcohol and substance abuse to R.W.O.